Acquisition Opportunity Bioness was acquired by Accelmed in 2024, signaling strategic growth and potential channel shifts. Engage to understand new corporate priorities, integration plans, and potential partnerships or OEM opportunities aligned with Accelmed’s HealthTech portfolio.

Medical Tech Expansion The company focuses on functional electrical stimulation systems, robotic systems, and software therapies for CNS disorders. This presents cross-sell potential with hardware, rehab robotics, and digital therapeutics to clinics, hospitals, and payer-near segments.

Growth and Scale Estimated revenue range of 25–50 million and a mid-sized employee base indicate a company at scale but with growth room. Position value propositions around scalable solutions, service contracts, and training programs for expanding clinical adoption.

Strategic Partnerships Recent and historical activity shows collaboration with clinics and international partners, plus a patient registry initiative. There is opportunity to propose joint ventures, clinical study collaborations, and registry-enabled data analytics services.

IP and Compliance Past litigation and patent-related disputes underscore a sensitivity around IP and regulatory risk. Offer services in IP due diligence, compliance consulting, and risk mitigation for new product launches or expansions.